NYSEAMERICAN:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.28 -0.02 (-5.47%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsBuy This Stock About AIM ImmunoTech Stock (NYSEAMERICAN:AIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AIM ImmunoTech alerts:Sign Up Key Stats Today's Range$0.26▼$0.2950-Day Range$0.23▼$0.9052-Week Range$0.21▼$20.35Volume815,429 shsAverage Volume16.27 million shsMarket Capitalization$4.08 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments. In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways. Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market. AI Generated. May Contain Errors. Read More AIM ImmunoTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreAIM MarketRank™: AIM ImmunoTech scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialAIM ImmunoTech has a consensus price target of $9.00, representing about 3,137.4% upside from its current price of $0.28.Amount of Analyst CoverageAIM ImmunoTech has only been the subject of 1 research reports in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.63) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted22.01% of the float of AIM ImmunoTech has been sold short.Short Interest Ratio / Days to CoverAIM ImmunoTech has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AIM ImmunoTech has recently decreased by 54.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentAIM ImmunoTech has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AIM ImmunoTech this week, compared to 3 articles on an average week.Search Interest31 people have searched for AIM on MarketBeat in the last 30 days. This is an increase of 417% compared to the previous 30 days.MarketBeat Follows4 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.Percentage Held by Insiders0.95% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by Institutions12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Stock News HeadlinesAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesJune 24, 2026 | globenewswire.comAIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New ExperiencesJune 23, 2026 | businesswire.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.June 30 at 1:00 AM | Weiss Ratings (Ad)AIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesJune 22, 2026 | globenewswire.comAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic CancerJune 18, 2026 | globenewswire.comAIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay AreaJune 17, 2026 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyJune 15, 2026 | finanznachrichten.deAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyJune 15, 2026 | globenewswire.comSee More Headlines AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $1.1289 at the beginning of 2026. Since then, AIM shares have decreased by 75.4% and is now trading at $0.2780. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.69) EPS for the quarter. The firm earned $0.02 million during the quarter. When did AIM ImmunoTech's stock split? AIM ImmunoTech shares reverse split on the morning of Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Gold Resource (GORO), 36Kr (KRKR), Ocean Power Technologies (OPTT), Aemetis (AMTX), Avino Silver & Gold Mines (ASM), eMagin (EMAN) and EMX Royalty (EMX). Company Calendar Last Earnings5/15/2026Today6/30/2026AGM 20267/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:AIM Previous SymbolNYSEAMERICAN:HEB CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees20Year Founded1990Price Target and Rating Average Price Target for AIM ImmunoTech$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+3,114.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($24.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.96 million Net Margins-14,123.40% Pretax Margin-14,123.40% Return on EquityN/A Return on Assets-177.72% Debt Debt-to-Equity Ratio0.10 Current Ratio1.01 Quick Ratio1.01 Sales & Book Value Annual Sales$90 thousand Price / Sales45.30 Cash FlowN/A Price / Cash FlowN/A Book Value($2.99) per share Price / Book-0.09Miscellaneous Outstanding Shares14,560,000Free Float14,426,000Market Cap$4.08 million OptionableNot Optionable Beta1.18 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSEAMERICAN:AIM) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles — con...Smallcaps Daily | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
